Recently, studies on targeted therapy have pointed out that there are many potential mutations in biliary tract cancer such as mutations of P53 [25], HER2 [26] and other molecular vulnerabilities, which can be used as therapeutic targets. The gene discussed is TP53; the disease is biliary tract neoplasm.